Basic Information
Hetronifly
Regulatory Information
EMEA/H/C/006170
February 3, 2025
September 19, 2024
2
May 5, 2025
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Hetronifly in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Overview Summary
Hetronifly is a cancer medicine used in adults to treat small cell lung cancer (SCLC) that has grown extensively in the lung or spread to other parts of the body (extensive-stage SCLC) and has not been treated previously. It is given together with carboplatin and etoposide (chemotherapy medicines). SCLC is rare, and Hetronifly was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 09 December 2022. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2731). Hetronifly contains the active substance serplulimab.